China Shineway Pharmaceutical Group Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de China Shineway Pharmaceutical Group de 8.3% y 12.8% por año respectivamente. Se prevé que el BPA crezca en un 7.5% al año. Se espera que la rentabilidad financiera sea de 14.7% en 3 años.
Información clave
8.3%
Tasa de crecimiento de los beneficios
7.5%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 10.8% |
| Tasa de crecimiento de los ingresos | 12.8% |
| Rentabilidad financiera futura | 14.7% |
| Cobertura de analistas | Low |
| Última actualización | 13 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
China Shineway Pharmaceutical Group Limited's (HKG:2877) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Oct 18
If EPS Growth Is Important To You, China Shineway Pharmaceutical Group (HKG:2877) Presents An Opportunity
Jun 03Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?
May 13China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461
Apr 26Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?
Apr 17China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461
Mar 31China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings
Mar 14Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?
Jan 29China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly
Sep 28China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118
Sep 01We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Aug 03Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?
May 30We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Mar 07China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125
Sep 01China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 31China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Apr 07China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.
Mar 11Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?
Feb 18
Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?
Jan 31Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?
Jan 13What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?
Dec 25We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease
Dec 10Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years
Nov 25Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 5,703 | 1,339 | 1,323 | 1,422 | 3 |
| 12/31/2025 | 4,925 | 1,180 | 785 | 972 | 3 |
| 12/31/2024 | 4,326 | 1,087 | 877 | 1,189 | 3 |
| 6/30/2024 | 4,205 | 1,105 | 1,072 | 1,175 | N/A |
| 3/31/2024 | 4,361 | 1,037 | 930 | 1,054 | N/A |
| 12/31/2023 | 4,517 | 970 | 788 | 933 | N/A |
| 9/30/2023 | 4,525 | 926 | 795 | 957 | N/A |
| 6/30/2023 | 4,534 | 883 | 801 | 982 | N/A |
| 3/31/2023 | 4,242 | 803 | 891 | 1,046 | N/A |
| 12/31/2022 | 3,951 | 723 | 980 | 1,110 | N/A |
| 9/30/2022 | 3,718 | 651 | 814 | 941 | N/A |
| 6/30/2022 | 3,485 | 579 | 648 | 772 | N/A |
| 3/31/2022 | 3,354 | 568 | 629 | 738 | N/A |
| 12/31/2021 | 3,224 | 557 | 610 | 703 | N/A |
| 9/30/2021 | 3,122 | 453 | 609 | 690 | N/A |
| 6/30/2021 | 3,020 | 350 | 608 | 677 | N/A |
| 3/31/2021 | 2,838 | 322 | 590 | 658 | N/A |
| 12/31/2020 | 2,656 | 295 | 573 | 639 | N/A |
| 9/30/2020 | 2,592 | 382 | 485 | 561 | N/A |
| 6/30/2020 | 2,528 | 469 | 397 | 483 | N/A |
| 3/31/2020 | 2,617 | 486 | 337 | 426 | N/A |
| 12/31/2019 | 2,706 | 503 | 277 | 368 | N/A |
| 9/30/2019 | 2,670 | 520 | 289 | 382 | N/A |
| 6/30/2019 | 2,633 | 537 | 301 | 396 | N/A |
| 3/31/2019 | 2,602 | 521 | 347 | 465 | N/A |
| 12/31/2018 | 2,570 | 506 | 393 | 533 | N/A |
| 9/30/2018 | 2,492 | 516 | 390 | 521 | N/A |
| 6/30/2018 | 2,413 | 526 | 388 | 509 | N/A |
| 3/31/2018 | 2,166 | 489 | N/A | 500 | N/A |
| 12/31/2017 | 1,920 | 452 | N/A | 491 | N/A |
| 9/30/2017 | 1,897 | 474 | N/A | 588 | N/A |
| 6/30/2017 | 1,873 | 496 | N/A | 685 | N/A |
| 3/31/2017 | 1,933 | 542 | N/A | 709 | N/A |
| 12/31/2016 | 1,993 | 589 | N/A | 734 | N/A |
| 9/30/2016 | 1,935 | 569 | N/A | 709 | N/A |
| 6/30/2016 | 1,877 | 549 | N/A | 685 | N/A |
| 3/31/2016 | 1,966 | 603 | N/A | 715 | N/A |
| 12/31/2015 | 2,055 | 658 | N/A | 745 | N/A |
| 9/30/2015 | 2,147 | 672 | N/A | 723 | N/A |
| 6/30/2015 | 2,239 | 685 | N/A | 701 | N/A |
| 3/31/2015 | 2,234 | 695 | N/A | 737 | N/A |
| 12/31/2014 | 2,229 | 705 | N/A | 773 | N/A |
| 9/30/2014 | 2,228 | 704 | N/A | 740 | N/A |
| 6/30/2014 | 2,227 | 703 | N/A | 706 | N/A |
| 3/31/2014 | 2,207 | 693 | N/A | 613 | N/A |
| 12/31/2013 | 2,187 | 684 | N/A | 520 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (8.3% al año) de 2877 es superior a la tasa de ahorro (2.3%).
Beneficios vs. Mercado: Se prevé que los beneficios (8.3% al año) de 2877 crezcan menos que el mercado Hong Kong (11.6% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de 2877 crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (12.8% al año) de 2877 crezcan más rápidamente que los del mercado Hong Kong (7.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 12.8% al año) de 2877 crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de 2877 sea baja dentro de 3 años (14.7%).